SAM
NKTR icon

Smartleaf Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Smartleaf Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131 Hold
2
– – ﹤0.01% 3347
2026
Q1 		$130 Hold
2
– – ﹤0.01% 3380
2025
Q4 		$84 Buy
+2
New +$112 ﹤0.01% 3409
2024
Q4 		– Sell
-19
Closed -$329 – 2984
2024
Q3 		$329 Buy
+19
New +$362 ﹤0.01% 2835

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Smartleaf Asset Management's NKTR Position: Q2 2026 in Review

Smartleaf Asset Management held its Nektar Therapeutics (NKTR) position steady in Q2 2026 at 2 shares worth $131. The position accounts for ﹤0.01% of the portfolio, ranked #3347.

Smartleaf Asset Management first reported a position in NKTR in Q3 2024 and has held it in 4 quarters since. The position peaked at $329 in Q3 2024. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Smartleaf Asset Management held 2 shares of Nektar Therapeutics worth $131 as of Q2 2026.
  • Smartleaf Asset Management left its Nektar Therapeutics share count unchanged in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #3347 holding.
  • Smartleaf Asset Management first reported a position in Nektar Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Smartleaf Asset Management's Nektar Therapeutics position peaked at $329 in Q3 2024.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.